Navigation Links
Medical Device Industry Executive Joins OrthoAccel Technologies, Inc. Board of Directors

HOUSTON, Oct. 14 /PRNewswire/ -- OrthoAccel Technologies, Inc., developers of the AcceleDent System, an acceleration device to enhance orthodontics, announced this week that it has engaged Todd Cooper as a Director on its Corporate Board.  Mr. Cooper's directorship will involve oversight and corporate governance of the Company's business strategy, with a focus on market growth.



AcceleDent is a simple, removable dental device that an orthodontic patient wears in the mouth for 20 minutes daily to accelerate orthodontic tooth movement.  A Phase I clinical trial in 2008 in Houston, Texas demonstrated the safety of the device.  The first completed AcceleDent case in private practice was documented earlier this month in the United Kingdom.

Mr. Cooper's background is particularly relevant to OrthoAccel's development of the AcceleDent brand.  His extensive experience includes general management, sale, marketing and product development on a global basis.  While at Discus, a market leader across numerous dental aesthetic  product categories, his leadership resulted in aggressive revenue growth and increasing profitability.  Most recently, Mr. Cooper managed the $400 million medical surgical business at Henry Schein, a $6.5 billion life sciences company.

Michael Lowe, CEO of OrthoAccel, commented, "We knew immediately that Todd's insight could help us shape our strategic direction.  There are many important parallels between OrthoAccel and the businesses that he has successfully managed in the past."  Mr. Cooper remarked, "AcceleDent can revolutionize the orthodontic market space and has huge market potential globally, much like Discus' whitening products did in the aesthetic space. AcceleDent addresses the fundamental desire by patients to shorten the time they need to use orthodontic appliances. I look forward to actively working with the Board and Management Team to build a strong global business."

Last month, OrthoAccel attended the British Orthodontic Conference, where it hosted a reception to feature the learnings from a select group of orthodontic specialist doctors who had been using the product for about a year.  Later this month, a lecture series will be held in Australia, where the device is also available, to further generate awareness around the AcceleDent science and favorable clinical outcomes.  This event is being coordinated in conjunction with AB Orthodontics, the exclusive distributor of AcceleDent in Australia.

OrthoAccel is nearing conclusion of another US clinical trial at the UT Health Science Center in San Antonio with an anticipated completion date in 2010.

About OrthoAccel Technologies, Inc.

Based in Houston, Texas, OrthoAccel Technologies, Inc. is a privately owned medical device company currently engaged in the development, manufacturing, and marketing of products to enhance dental care and orthodontic treatment.

About the AcceleDent System

AcceleDent represents the first clinical approach to safely accelerate orthodontic tooth movement via modulating biology.  The device has been studied clinically and applies gentle pulsing forces in combination with standard orthodontics to move teeth faster through accelerated bone remodeling.  Importantly, the device works complementary with all existing orthodontic technologies.  AcceleDent is neither FDA cleared nor FDA approved; it is currently investigational only in the United States.  More information can be found at or requested via

SOURCE OrthoAccel Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology:
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):